JPH08505640A - 安定な経口用のci−981製剤およびその製法 - Google Patents
安定な経口用のci−981製剤およびその製法Info
- Publication number
- JPH08505640A JPH08505640A JP6517015A JP51701594A JPH08505640A JP H08505640 A JPH08505640 A JP H08505640A JP 6517015 A JP6517015 A JP 6517015A JP 51701594 A JP51701594 A JP 51701594A JP H08505640 A JPH08505640 A JP H08505640A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- calcium
- weight
- drug
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.混合物中に、活性成分として構造式 〔式中、 Xは、-CH2-、-CH2CH2-、-CH2CH2CH2-または-CH2CH(CH3)-であり; R1は、1‐ナフチル;2‐ナフチル;シクロヘキシル;ノルボルネニル;2‐ 、3‐または4‐ピリジニル;フェニル;弗素、塩素、臭素、ヒドロキシル、ト リフルオロメチル、1〜4個の炭素原子のアルキル、1〜4個の炭素原子のアル コキシまたは2〜8個の炭素原子のアルカノイルアルコキシにより置換されたフ ェニルであり; R2またはR3の一方は、-C0NR5R6(式中、R5およびR6は、独立して水素;1〜6 個の炭素原子のアルキル;2‐、3‐または4‐ピリジニル;フェニル;弗素、 塩素、臭素、シアノ、トリフルオロメチルまたは3〜8個の炭素原子のカルボア ルコキシにより置換されたフェニルである)でありそしてR2またはR3の他方は、 水素;1〜6個の炭素原子のアルキル;シクロプロピル;シクロブチル;シクロ ペンチル;シクロヘキシル;フェニル;または弗素、塩素、臭素、ヒドロキシル 、トリフルオロメチル、1〜4個の炭素原子のアルキル、1〜4個の炭素原子の アルコキシまたは2〜8個の炭素原子のアルカノイルオキシにより置換されたフ ェニル であり; R4は、1〜6個の炭素原子のアルキル;シクロプロピル;シクロブチル;シク ロペンチル;シクロヘキシル;またはトリフルオロメチルであり;そしてMは、 医薬的に許容し得る金属塩である〕の化合物および少なくとも1種の医薬的に許 容し得る安定化金属塩添加剤を含有する改善された安定性によって特徴づけられ る高コレステロール血症または高脂質血症の経口治療用の医薬組成物。 2.活性成分が、〔R‐(R*,R*)〕‐2‐(4‐フルオロフェニル)‐β,δ‐ジ ヒドロキシ‐5‐(1‐メチルエチル)‐3‐フェニル‐4‐〔(フェニルアミ ノ)カルボニル)‐1H‐ピロール‐1‐ヘプタン酸の医薬的に許容し得る金属塩 である請求項1記載の安定な医薬組成物。 3.Mが医薬的に許容し得るアルカリ土類金属塩である請求項1記載の安定な医 薬組成物。 4.医薬的に許容し得る金属塩がアルカリ土類金属塩である請求項2記載の安定 な医薬組成物。 5.医薬的に許容し得る安定化添加剤がアルカリ土類金属塩である請求項1記載 の安定な医薬組成物。 6.アルカリ土類金属塩が、炭酸カルシウム、水酸化カルシウム、炭酸マグネシ ウム、水酸化マグネシウム、珪酸マグネシウム、アルミン酸マグネシウムおよび 水酸化マグネシウムアルミニウムからなる群から選択されたものである請求項5 記載の安定な医薬組成物。 7.医薬的に許容し得る安定化添加剤が炭酸カルシウムである請求 項1記載の安定な医薬組成物。 8.活性成分が式(IA): のCI-981 半‐カルシウムでありそして医薬的に許容し得る安定化添加剤が炭酸 カルシウムである請求項2記載の安定な医薬組成物。 9.さらに、結合剤、希釈剤、崩壊剤、表面活性剤、滑沢剤および抗酸化剤の形 態の他の成分を含有する請求項1記載の安定な医薬組成物。 10.活性成分の使用量が組成物の約1〜50重量%である請求項1、2または8記 載の安定な医薬組成物。 11.安定剤炭酸カルシウムが、組成物の約5〜75重量%の範囲にある請求項7記 載の安定な医薬組成物。 12.他の成分が、全体の固体の組成物の約5〜75重量%の微小結晶セルロース; 約1〜80重量%の含水ラクトース;約1〜15重量%のクロスカルメロースナトリ ウム;約0.5〜6重量%のヒドロキシプロピルセルロース;約0.1〜4重量%のト ゥイーン80;約0.25〜2重量%のステアリン酸マグネシウムおよび約3重量%ま でのアスコルビン酸ナトリウムまたはブチル化ヒドロキシアニソールからなる請 求項9記載の安定な医薬組成物。 13.固体の単位使用形態中に、活性成分〔R‐(R*,R*)〕‐2‐(4 ‐フルオロフェニル)‐β,δ‐ジヒドロキシ‐5‐(1‐メチルエチル)‐3 ‐フェニル‐4‐〔(フェニルアミノ)カルボニル〕‐1H−ピロール‐1‐ヘプ タン酸 半‐カルシウム塩および炭酸カルシウム、水酸化カルシウム、炭酸マグ ネシウム、水酸化マグネシウム、珪酸マグネシウム、アルミン酸マグネシウムお よび水酸化マグネシウムアルミニウムからなる群から選択された安定剤を含有す る高コレステロール血症または高脂質血症の経口治療用の安定化された固体の医 薬組成物。 14.請求項1、2または8記載の活性成分約1〜50重量%を医薬的に許容し得る 安定化添加剤約5〜75重量%と十分に混合する工程からなる高コレステロール血 症または高脂質血症の経口治療用の安定な医薬組成物の製法。 15.さらに、少なくとも1種の結合剤、希釈剤、崩壊剤、表面活性剤、滑沢剤ま たは抗酸化剤を含有する混合物を加える工程からなる請求項14記載の方法。 16.(a)式IA の薬剤CI-981 半‐カルシウムの過剰を微粉砕化し; (b)少なくとも1種の結合剤添加物を、表面活性剤水溶液に溶解し; (c)微粉砕化した薬剤を、チョッピング装置を具備した回転 混合容器中において、少なくとも1種の薬剤‐安定化添加剤および該薬剤‐安定 化添加剤と一緒に少なくとも1種希釈剤添加物および崩壊剤添加物の半量と混合 し; (d)チョッパーを具備した混合容器中において、工程(c)の混合した薬剤混 合物を徐々な増加量の工程(b)の表面活性剤/結合剤溶液で造粒し; (e)造粒した薬剤混合物を約50℃で一夜乾燥し; (f)乾燥した造粒薬剤混合物をふるいにかけ; (g)ふるいにかけた薬剤混合物を残りの量の崩壊剤添加物と回転混合し; (h)工程(g)の薬剤混合物のアリコートを別個にステアリン酸マグネシウム と混合し、これをふるいにかけそしてこれを工程(g)の薬剤混合物に戻しそし て全体の薬剤混合物を回転混合し;そして工程(h)の薬剤混合物のアリコート を圧縮して適当な薬剤濃度を有する錠剤を得ることからなる高コレステロール血 症または高脂質血症の経口的治療のために処方された安定された医薬組成物の製 法。 17.工程(c)において、薬剤安定化添加剤がカルシウムまたはマグネシウムの 塩基性無機塩からなりそして希釈剤添加物が微小結晶セルロース、含水ラクトー ス、とうもろこし殿粉、スクロース、無水珪酸または多糖類からなる請求項16記 載の方法。 18.工程(b)において、結合剤添加物がメチルセルロース、カルボキシメチル セルロース、ヒドロキシプロピルセルロース、ヒドロキシメチルセルロース、ポ リビニルピロリドン、ポリビニルアルコールまたは殿粉からなりそして表面活性 剤がトゥイーン80また はポリオキシエチレン‐ポリオキシプロピレン共重合体からなる請求項16記載の 方法。 19.工程(c)において、崩壊剤添加剤がクロスカルメロースナトリウム、カル ボキシメチルセルロースカルシウムまたは殿粉からなる請求項16記載の方法。 20.1日につき体重1k9当り約0.1〜8.0mgの範囲の投与量において、炭酸カルシ ウムにより安定化されたエナンチオマー〔R‐(R*,R*)〕‐2‐(4‐フルオロ フェニル)‐β‐,δ‐ジヒドロキシ‐5‐(1‐メチルエチル)‐3‐フェニ ル‐4‐〔(フェニルアミノ)カルボニル〕‐1H‐ピロール‐1‐ヘプタン酸 半‐カルシウムの有効なコレステロール合成阻害量を含有する高コレステロール 血症を治療するための経口用医薬組成物。 21.錠剤またはカプセルの形態の請求項20記載の経口用医薬組成物の治療的に有 効な単位投与量を投与することからなる高コレステロール血症または高脂質血症 を治療する方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US570893A | 1993-01-19 | 1993-01-19 | |
US005,708 | 1993-01-19 | ||
US08/005,708 | 1993-01-19 | ||
PCT/US1993/012471 WO1994016693A1 (en) | 1993-01-19 | 1993-12-20 | Stable oral ci-981 formulation and process of preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08505640A true JPH08505640A (ja) | 1996-06-18 |
JP3254219B2 JP3254219B2 (ja) | 2002-02-04 |
Family
ID=21717295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51701594A Expired - Lifetime JP3254219B2 (ja) | 1993-01-19 | 1993-12-20 | 安定な経口用のci−981製剤およびその製法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US5686104A (ja) |
EP (1) | EP0680320B1 (ja) |
JP (1) | JP3254219B2 (ja) |
AT (1) | ATE178794T1 (ja) |
CA (1) | CA2150372C (ja) |
CY (1) | CY2128B1 (ja) |
DE (1) | DE69324504T2 (ja) |
DK (1) | DK0680320T3 (ja) |
ES (1) | ES2133158T3 (ja) |
GR (1) | GR3030359T3 (ja) |
MX (1) | MX9400281A (ja) |
SA (1) | SA01220291A (ja) |
SG (1) | SG45369A1 (ja) |
WO (1) | WO1994016693A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001206847A (ja) | 2000-01-26 | 2001-07-31 | Astrazeneca Ab | 医薬組成物 |
JP2002532429A (ja) * | 1998-12-15 | 2002-10-02 | ギリアード サイエンシーズ, インコーポレイテッド | 薬学的処方物 |
JP2004501121A (ja) * | 2000-06-09 | 2004-01-15 | エルイーケー ファーマシューティカルズ ディー.ディー. | 安定した医薬効果を有する合成物、及びそれを含む医薬製剤 |
JP2006527260A (ja) * | 2003-06-12 | 2006-11-30 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 湿式顆粒化で調製されたアトルバスタチンの安定な組成物 |
JP2010095490A (ja) * | 2008-10-20 | 2010-04-30 | Nipro Corp | 錠剤の製造方法 |
JP2012036197A (ja) * | 2004-05-05 | 2012-02-23 | Pfizer Products Inc | アトルバスタチンの塩形態 |
WO2012042951A1 (ja) * | 2010-09-30 | 2012-04-05 | アステラス製薬株式会社 | アトルバスタチン含有医薬錠剤 |
WO2014002851A1 (ja) * | 2012-06-25 | 2014-01-03 | ニプロ株式会社 | 固形医薬錠剤およびその製造方法 |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514533B1 (en) * | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US20110196039A9 (en) * | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
DE19725391A1 (de) * | 1997-06-16 | 1998-12-17 | Bayer Ag | Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
ATE288893T1 (de) * | 1999-11-17 | 2005-02-15 | Teva Pharma | Polymorphe form von atorvastatin-calcium |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
ES2401598T3 (es) | 2000-04-10 | 2013-04-22 | Teva Pharmaceutical Industries, Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
DE60041281D1 (de) † | 2000-06-09 | 2009-02-12 | Lek Pharmaceuticals | Stabilisiertes arzneimittel und arzneizubereitung |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
MXPA03005879A (es) * | 2000-12-27 | 2003-09-10 | Ciba Sc Holding Ag | Formas cristalinas de atorvastatina. |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
ATE318272T1 (de) | 2001-04-11 | 2006-03-15 | Bristol Myers Squibb Co | Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren |
IN190564B (ja) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
AP1571A (en) | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
WO2003004456A1 (en) * | 2001-07-06 | 2003-01-16 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
US20030044459A1 (en) * | 2001-09-04 | 2003-03-06 | Pfizer Inc. | Biomodulated multiparticulate formulations |
GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
KR20040054729A (ko) * | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US6806381B2 (en) * | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
EP1443919A4 (en) * | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
EA200401059A1 (ru) * | 2002-02-14 | 2005-02-24 | Рэнбакси Лабораториз Лимитед | Композиции аторвастатина, стабилизированные добавками щелочных металлов |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
JP4478563B2 (ja) * | 2002-05-14 | 2010-06-09 | プレゼント インヴェストメンツ エルエルシー | 送信信号の形成方法 |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
ES2344057T3 (es) * | 2002-10-23 | 2010-08-17 | Bristol-Myers Squibb Company | Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina. |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
ES2300628T3 (es) * | 2002-12-20 | 2008-06-16 | Pfizer Products Inc. | Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa. |
JP2006513186A (ja) * | 2002-12-20 | 2006-04-20 | ファイザー・プロダクツ・インク | Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形 |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
US7557143B2 (en) | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
EP1636183A1 (en) * | 2003-05-16 | 2006-03-22 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
RU2006102981A (ru) * | 2003-08-04 | 2007-09-20 | Пфайзер Продактс Инк. (Us) | Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы |
DE602004010817T2 (de) * | 2003-08-05 | 2008-12-11 | Zentiva, A.S. | Verfahren zur stabilisierung von atorvastatin |
EP1663969A1 (en) * | 2003-09-17 | 2006-06-07 | Warner-Lambert Company LLC | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
TR200301614A2 (tr) * | 2003-09-26 | 2005-10-21 | Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem |
WO2005047297A1 (en) * | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
PT1532975E (pt) * | 2003-11-18 | 2007-04-30 | Helm Ag | Processo para a preparação de advorvidos de atorvastatina fluídos em pó |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
ES2381473T3 (es) | 2004-03-17 | 2012-05-28 | Ranbaxy Laboratories Limited | Procedimiento para la preparación de atorvastatina cálcica en forma amorfa |
WO2005100313A1 (en) * | 2004-04-16 | 2005-10-27 | Pfizer Products Inc. | Process for forming amorphous atorvastatin calcium |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
US7786163B2 (en) * | 2004-07-12 | 2010-08-31 | Forest Laboratories Holdings Limited (BM) | Constrained cyano compounds |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
EP1771455B1 (en) * | 2004-07-16 | 2016-05-11 | LEK Pharmaceuticals d.d. | Oxidative degradation products of atorvastatin calcium |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
JP2008509154A (ja) * | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なスタチン薬剤組成物および関連治療方法 |
NZ552390A (en) * | 2004-08-06 | 2010-01-29 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
NZ554541A (en) | 2004-10-28 | 2011-01-28 | Warner Lambert Co | Process for forming amorphous atorvastatin |
EP1814541A4 (en) | 2004-11-22 | 2009-10-28 | Dexcel Pharma Technologies Ltd | STABLE ATORVASTATIN FORMULATIONS |
WO2006059224A1 (en) * | 2004-12-02 | 2006-06-08 | Warner-Lambert Company Llc | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
WO2006070248A1 (en) * | 2004-12-28 | 2006-07-06 | Ranbaxy Laboratories Limited | Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine |
US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2006076597A1 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) * | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7220859B2 (en) | 2005-01-12 | 2007-05-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006082500A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
US7238702B2 (en) * | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CN101282991A (zh) * | 2005-05-26 | 2008-10-08 | 布里斯托尔-迈尔斯斯奎布公司 | N-端修饰的胰高血糖素样肽-1受体调节剂 |
US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
EP1919466B9 (en) | 2005-07-11 | 2012-05-16 | Cortria Corporation | Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative |
EP1910361A2 (en) * | 2005-07-28 | 2008-04-16 | Brystol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
BRPI0614280A2 (pt) * | 2005-08-15 | 2009-08-04 | Arrow Int Ltd | atorvastatina sódica cristalina e amorfa |
CA2619486C (en) * | 2005-08-15 | 2015-05-12 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
WO2007035395A2 (en) * | 2005-09-16 | 2007-03-29 | Virginia Commonwealth University Intellectual Property Foundation | Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
DK1957452T3 (da) * | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US20090123543A1 (en) * | 2006-01-02 | 2009-05-14 | Rubicon Research Private Limited | Pharmaceutical compositions |
EP1976873A2 (en) * | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
EP1818049A3 (en) | 2006-02-10 | 2008-11-19 | LifeCycle Pharma A/S | Stabilized Atorvastatin |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
ES2376396T3 (es) | 2006-06-26 | 2012-03-13 | Amgen Inc. | Método para tratar aterosclerosis. |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
WO2008117154A2 (en) * | 2007-03-26 | 2008-10-02 | Torrent Pharmaceuticals Limited | Stable pharmaceutical compositions of hmg-coa reductase inhibitor and process for preparation thereof |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
CN101795684A (zh) * | 2007-04-09 | 2010-08-04 | 赛多斯有限责任公司 | 他汀类化合物与抗肥胖药的组合 |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
EP2581081A3 (en) | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
ES2513716T3 (es) | 2007-07-26 | 2014-10-27 | Amgen, Inc | Enzimas lecitina-colesteros acitransferasa modificadas |
JP2010534644A (ja) * | 2007-07-27 | 2010-11-11 | シプラ・リミテッド | 医薬組成物およびその製造方法 |
JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
EP2209780B1 (en) | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
US20090226516A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Sartan compositions |
US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
WO2010111665A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
HUE040486T2 (hu) | 2009-11-13 | 2019-03-28 | Astrazeneca Ab | Kétrétegû tabletta készítmények |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
EP2498757A1 (en) | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
AU2011276254B2 (en) | 2010-07-09 | 2016-11-03 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
EP2726456A1 (en) | 2011-07-01 | 2014-05-07 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Micronized crystals of atorvastatin hemicalcium |
WO2013072770A2 (en) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
TW201329104A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 人類lcat抗原結合蛋白質及其治療用途 |
CN104244946A (zh) | 2012-04-30 | 2014-12-24 | 霍夫曼-拉罗奇有限公司 | 新制剂 |
NZ707859A (en) | 2012-11-20 | 2019-03-29 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
CN103705484B (zh) * | 2014-01-03 | 2015-05-20 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的阿托伐他汀钙片及其制备方法 |
CN104069078B (zh) * | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | 阿托伐他汀钙药物组合物及其制备方法 |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
JP2018515082A (ja) | 2015-04-30 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害を処置するための抗ap2抗体及び抗原結合剤 |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
TWI663979B (zh) * | 2018-03-20 | 2019-07-01 | 菲利達生技股份有限公司 | 用於抗發炎之套組 |
BR112021004839A2 (pt) | 2018-09-26 | 2021-06-08 | Lexicon Pharmaceuticals, Inc. | formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6156171A (ja) * | 1984-07-03 | 1986-03-20 | ザ ウエルカム フアウンデ−シヨン リミテツド | 抗ウイルス性化合物 |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
WO1989002265A1 (en) * | 1987-09-07 | 1989-03-23 | Teijin Limited | Medicine-containing fat emulsion of the type prepared immediately before use and process for preparing medicine-containing fat emulsion |
JPH026406A (ja) * | 1988-03-31 | 1990-01-10 | E R Squibb & Sons Inc | 安定性良好な医薬組成物 |
JPH0273078A (ja) * | 1988-07-19 | 1990-03-13 | Merck & Co Inc | メビン酸及びその類似体のラクトン化方法 |
JPH0358967A (ja) * | 1989-07-21 | 1991-03-14 | Warner Lambert Co | 〔R―(R‖,R‖)〕―2―(4―フルオロフエニル)―β,δ―ジヒドロキシ―5―(1―メチルエチル)―3―フエニル―4―〔(フエニルアミノ)カルボニル〕―1H―ピロール―1―ヘプタン酸、そのラクトン体およびその塩 |
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPH03163018A (ja) * | 1990-11-20 | 1991-07-15 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
US5093132A (en) * | 1986-02-13 | 1992-03-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
-
1993
- 1993-12-20 AT AT94904881T patent/ATE178794T1/de not_active IP Right Cessation
- 1993-12-20 WO PCT/US1993/012471 patent/WO1994016693A1/en active IP Right Grant
- 1993-12-20 DE DE69324504T patent/DE69324504T2/de not_active Expired - Lifetime
- 1993-12-20 DK DK94904881T patent/DK0680320T3/da active
- 1993-12-20 EP EP94904881A patent/EP0680320B1/en not_active Expired - Lifetime
- 1993-12-20 SG SG1996005027A patent/SG45369A1/en unknown
- 1993-12-20 CA CA002150372A patent/CA2150372C/en not_active Expired - Lifetime
- 1993-12-20 JP JP51701594A patent/JP3254219B2/ja not_active Expired - Lifetime
- 1993-12-20 ES ES94904881T patent/ES2133158T3/es not_active Expired - Lifetime
-
1994
- 1994-01-05 MX MX9400281A patent/MX9400281A/es not_active IP Right Cessation
- 1994-05-20 US US08/246,919 patent/US5686104A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 US US08/886,982 patent/US6126971A/en not_active Expired - Lifetime
-
1999
- 1999-05-27 GR GR990401451T patent/GR3030359T3/el unknown
- 1999-05-28 CY CY9900012A patent/CY2128B1/xx unknown
-
2001
- 2001-08-19 SA SA01220291A patent/SA01220291A/ar unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6156171A (ja) * | 1984-07-03 | 1986-03-20 | ザ ウエルカム フアウンデ−シヨン リミテツド | 抗ウイルス性化合物 |
US5093132A (en) * | 1986-02-13 | 1992-03-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
WO1989002265A1 (en) * | 1987-09-07 | 1989-03-23 | Teijin Limited | Medicine-containing fat emulsion of the type prepared immediately before use and process for preparing medicine-containing fat emulsion |
JPH026406A (ja) * | 1988-03-31 | 1990-01-10 | E R Squibb & Sons Inc | 安定性良好な医薬組成物 |
JPH0273078A (ja) * | 1988-07-19 | 1990-03-13 | Merck & Co Inc | メビン酸及びその類似体のラクトン化方法 |
JPH0358967A (ja) * | 1989-07-21 | 1991-03-14 | Warner Lambert Co | 〔R―(R‖,R‖)〕―2―(4―フルオロフエニル)―β,δ―ジヒドロキシ―5―(1―メチルエチル)―3―フエニル―4―〔(フエニルアミノ)カルボニル〕―1H―ピロール―1―ヘプタン酸、そのラクトン体およびその塩 |
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
JPH03163018A (ja) * | 1990-11-20 | 1991-07-15 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532429A (ja) * | 1998-12-15 | 2002-10-02 | ギリアード サイエンシーズ, インコーポレイテッド | 薬学的処方物 |
JP2001206847A (ja) | 2000-01-26 | 2001-07-31 | Astrazeneca Ab | 医薬組成物 |
JP2004501121A (ja) * | 2000-06-09 | 2004-01-15 | エルイーケー ファーマシューティカルズ ディー.ディー. | 安定した医薬効果を有する合成物、及びそれを含む医薬製剤 |
JP2006527260A (ja) * | 2003-06-12 | 2006-11-30 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 湿式顆粒化で調製されたアトルバスタチンの安定な組成物 |
JP2012036197A (ja) * | 2004-05-05 | 2012-02-23 | Pfizer Products Inc | アトルバスタチンの塩形態 |
JP2010095490A (ja) * | 2008-10-20 | 2010-04-30 | Nipro Corp | 錠剤の製造方法 |
WO2012042951A1 (ja) * | 2010-09-30 | 2012-04-05 | アステラス製薬株式会社 | アトルバスタチン含有医薬錠剤 |
JP5807642B2 (ja) * | 2010-09-30 | 2015-11-10 | アステラス製薬株式会社 | アトルバスタチン含有医薬錠剤 |
WO2014002851A1 (ja) * | 2012-06-25 | 2014-01-03 | ニプロ株式会社 | 固形医薬錠剤およびその製造方法 |
JPWO2014002851A1 (ja) * | 2012-06-25 | 2016-05-30 | ニプロ株式会社 | 固形医薬錠剤およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
DK0680320T3 (da) | 1999-10-25 |
WO1994016693A1 (en) | 1994-08-04 |
CA2150372C (en) | 2002-08-20 |
CY2128B1 (en) | 2002-06-21 |
CA2150372A1 (en) | 1994-08-04 |
EP0680320A1 (en) | 1995-11-08 |
ATE178794T1 (de) | 1999-04-15 |
MX9400281A (es) | 1994-07-29 |
DE69324504D1 (de) | 1999-05-20 |
ES2133158T3 (es) | 1999-09-01 |
DE69324504T2 (de) | 1999-08-26 |
EP0680320B1 (en) | 1999-04-14 |
US5686104A (en) | 1997-11-11 |
SG45369A1 (en) | 1998-10-16 |
GR3030359T3 (en) | 1999-09-30 |
SA01220291A (ar) | 2005-12-03 |
JP3254219B2 (ja) | 2002-02-04 |
US6126971A (en) | 2000-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08505640A (ja) | 安定な経口用のci−981製剤およびその製法 | |
BE1013414A5 (fr) | Compositions pharmaceutiques. | |
KR100905730B1 (ko) | 약제학적 형태의 아토르바스타틴 칼슘, 이의 조성물 및아토르바스타틴 칼슘을 함유하는 약제학적 제형 | |
US7718643B2 (en) | Pharmaceutical formulation | |
EP2229938B9 (en) | Ezetimibe compositions | |
US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
JP2005522444A (ja) | アルカリ金属の添加により安定化させたアトーバスタチン製剤 | |
WO2006070248A1 (en) | Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine | |
JP2012520281A (ja) | ロスバスタチンラクトールの薬物としての使用 | |
US20090292016A1 (en) | Stable Pharmaceutical Compositions Containing Pravastatin | |
US4666919A (en) | Stabilized pharmaceutical composition containing an isocarbostyril derivative | |
JP5765738B2 (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
US20080038332A1 (en) | Stable pharmaceutical formulation comprising atorvastatin calcium | |
EP0310999B1 (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
WO2003055467A1 (en) | Simvastatin dosage forms | |
JP5738205B2 (ja) | アトルバスタチンラクトールの薬物としての使用 | |
JPH0818987B2 (ja) | 経口用セフアロスポリン組成物 | |
EP1825848A2 (de) | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor | |
JP2002302443A (ja) | シンバスタチン含有製剤 | |
AU2002314915A1 (en) | Stable pharmaceutical compositions containing pravastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071122 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081122 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091122 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091122 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131122 Year of fee payment: 12 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
EXPY | Cancellation because of completion of term |